MICRONIZED PHENOFIBRATE ACTION ON PLASMA- LIPOPROTEINS IN VARIOUS BASE-LINE LIPIDS

Novel antihyperlipidemic micronized phenofibrate lipantil 200 M was te sted for safety and efficacy (one 200 mg capsule a day for 3 months) i n 27 patients having cholesterol level above 6.5 mmol/l. The effect em erged upon 1 month of administration and persisted till the end of the treatment. In combined hyperlipidemia triglycerides decreased by 45-6 0%, total cholesterol and LDL cholesterol by 10-12%. In isolated hyper lipidemia tile latter two values appeared lower by 20-23 and 22-27%, r espectively. After lipantil 200 M treatment HDL cholesterol went up by 9%, in low baseline level (<1 mmol/l) by 27%. No negative clinicobioc hemical shifts were seen, while fibrinogen and uric acid reduced by 16 %, apoB by 23-30%. Lipantil 200 M proved active against hyperlipidemia and is recommended for clinical practice.